Outlook blindsided as FDA blocks wet AMD drug once again
Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.
Novo reels in Replicate for new cardiometabolic drugs
Replicate will receive up to $550m from Novo Nordisk in an alliance that aims to deliver a new generation of drugs for obesity and diabetes.
Increasing trial efficiency: Adityo Prakash talks small data...
Adityo Prakash, founder and CEO of Verseon, discusses small datasets, real-world scenarios, and organoids.
Scoop: Lumos Labs has FDA nod for ADHD DtX Prismira
Lumos Labs has secured its first 510(k) clearance for a digital therapeutics offering, paving the way for entrance into the regulated app market.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
3rd Cell Therapy for Autoimmune Disease Summit
The industry’s definitive meeting advancing autoimmune cell therapies to market.
The 2nd Cell & Gene Therapy Regulatory Affairs Summit Return...
Navigate FDA changes & global alignment at the only CGT regulatory strategy summit.
Join the IMPACCT Real-World Evidence Summit West
Be at the forefront of the next era in evidence generation at the IMPACCT Real-World Evidence Summit West
2nd Innovation in Obesity Therapeutics Summit
Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly, and Boehringer Ingelheim, as well as innovative biotechs
Maximising the Therapeutic Potential of Complement Mediation...
Capturing the Industry’s Most Exciting Developments in Complement-Based Therapeutics